FDA Disagrees With GAO’s “Unusual” Findings Regarding Plan B Decision
This article was originally published in The Tan Sheet
Executive Summary
Reports from FDA officials vary as to the timing of the decision not to approve Barr's emergency contraceptive Plan B for over-the-counter sale, GAO's investigation into the application process reveals (see chart: "1Brief Timeline of Major Plan B Events Related to the Initial OTC Switch Application").